CD274 and neoplasm: While others have shown that OVs can be engineered to express secreted antibodies to antagonize immune checkpoint inhibitors Chen et al. demonstrate that the localized deletion of the PDL1 gene coupled with OA mediated oncolysis in the same vicinity as tumor targeted T cells appears to be sufficient to trigger a systemic, therapeutic immune response.